Vaccine hesitancy

NY Vaccine Literacy Campaign launches COVID-19 vaccine data dashboard

Retrieved on: 
Monday, November 22, 2021
Conditional sentence, Graduate Center, CUNY, Health, Prevalence, Health policy, COVID-19, Korea Disease Control and Prevention Agency, Parent, Vaccine hesitancy, Communication, CBO, Data visualization, Public health, CDC, CUNY, Andrew Kohut, Center, Health Resources and Services Administration, Pharmaceutical industry, Dietary supplement

NEW YORK, Nov. 22, 2021 /PRNewswire/ -- The NY Vaccine Literacy Campaign (NY VLC) at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) launched its COVID-19 data visualization dashboard today to provide actionable data drawn from nine counties in the New York area and support community-based organizations (CBOs) in COVID-19 education and outreach.

Key Points: 
  • NEW YORK, Nov. 22, 2021 /PRNewswire/ -- The NY Vaccine Literacy Campaign (NY VLC) at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) launched its COVID-19 data visualization dashboard today to provide actionable data drawn from nine counties in the New York area and support community-based organizations (CBOs) in COVID-19 education and outreach.
  • This follows the recent release of new data on COVID-19 vaccine attitudes and uptake among 1,000 respondents in the region, covering vaccine hesitancy and acceptance, including parents of children under 18 years old.
  • Led by Dr. Ashish Joshi, CUNY SPH professor and senior associate dean, and developed in conjunction with the NY VLC's Community Engagement Advisory Council, the data visualization dashboard and website will publicize survey data on vaccine sentiments across the nine lower NY counties.
  • Multiple data sources were utilized in the development of the dashboard to map vaccine coverage and areas of concern, including quarterly survey panel data conducted by the NY VLC and publicly available datasets from the Centers for Disease Control and Prevention (CDC).

CMA reacts to COVID-19 vaccine approval for 5 to 11 age group

Retrieved on: 
Friday, November 19, 2021
Patient, Pfizer–BioNTech COVID-19 vaccine, National Advisory Committee on Immunization, Health, Safety, Death, Hospital, Pfizer, COVID-19, Parent, Vaccine hesitancy, Risk, Disability, Science, CMA, NACI, Pharmaceutical industry

As we all look ahead to the end of the pandemic, the CMA reminds Canadians of the considerable work remaining to mitigate outbreaks namely, addressing misinformation and vaccine hesitancy.

Key Points: 
  • As we all look ahead to the end of the pandemic, the CMA reminds Canadians of the considerable work remaining to mitigate outbreaks namely, addressing misinformation and vaccine hesitancy.
  • We salute the work that has been done by the National Advisory Committee on Immunization (NACI) to thoroughly review the science behind the vaccine for this age group.
  • We know that many parents, and others, will have questions about the vaccine.
  • The CMA continues to align with NACI recommendations and urge Canadians to seek medical information and advice from the most trusted source of this informationhealth professionals.

The Alliance for Advancing Health Online Invests $7M+ through the Vaccine Confidence Fund to Boost Vaccination Confidence through Social Media

Retrieved on: 
Thursday, October 14, 2021
Online, Vaccine Confidence Project, Organization, Facebook, VCF, Technology, Immunization, Sabin Vaccine Institute, Program, Health equity, Merck, Social media, Vaccine-preventable diseases, Tropical medicine, Natural language processing, Hygiene, Vaccination, Theory, Public health, GLOBE, London School of Hygiene & Tropical Medicine, Global Impact, Merck & Co., Vaccine hesitancy, Indigenous peoples, Communication, Polio, Research, Anthrax Vaccine Immunization Program, Risk, COVID-19, Pharmaceutical industry

VCF is the first flagship program of the Alliance for Advancing Health Online (AAHO).

Key Points: 
  • VCF is the first flagship program of the Alliance for Advancing Health Online (AAHO).
  • The AAHOs mission is to bring together members from the technology, health, global development and academic sectors to advance public understanding of how social media and other online platforms can be leveraged to increase vaccination confidence and vaccine uptake.
  • Supporting the public health efforts to increase vaccine confidence has been our top priority, said KX Jin, Facebooks Head of Health.
  • Finally, more than half of the grantees will be investigating the connection between social media (online) and vaccine uptake (offline) through vaccination bookings and/or actual vaccinations via health clinics.

Best’s Commentary: Thailand Insurers Offer Innovative Vaccine Allergy Product, But Underwriting Risks Remain

Retrieved on: 
Friday, October 8, 2021
Infectious Diseases, Health, Professional Services, Pharmaceutical, Insurance, Risk, COVID-19, Industry, World Health Organization, AM Best, News, Risk management, Vaccine, World, Policy, Vaccine hesitancy, Insurance, ALL

In its Bests Commentary, Thailand Insurers Offer Innovative Vaccine Allergy Product, But Underwriting Risks Remain, AM Best states that with new variants having emerged, coupled with pockets of vaccine hesitancy, the recent introduction of vaccine allergy insurance cover provides a growth opportunity for Thailands life and non-life insurance segments, which were supported by robust health insurance demand in 2020.

Key Points: 
  • In its Bests Commentary, Thailand Insurers Offer Innovative Vaccine Allergy Product, But Underwriting Risks Remain, AM Best states that with new variants having emerged, coupled with pockets of vaccine hesitancy, the recent introduction of vaccine allergy insurance cover provides a growth opportunity for Thailands life and non-life insurance segments, which were supported by robust health insurance demand in 2020.
  • While domestic insurers in Thailand have been swift to capitalise on market opportunities amid the pandemic, AM Best notes the importance of insurers remaining on top of their risk exposure, given the uncertainty surrounding loss exposure.
  • COVID-19 vaccine profiles vary among manufacturers, and the World Health Organization has noted a lack of comprehensive quality data regarding the serious adverse effects of particular vaccines.
  • Positive or negative developments in these areas could bear material implications for Thailand insurers offering vaccine allergy insurance cover.

Ford Foundation Makes Widespread Commitments to Further Global Vaccine Access

Retrieved on: 
Wednesday, October 6, 2021
People, Charlize, Global South, Vaccine, Failure, Walker, Ford Foundation, Thought, Foundation (nonprofit), Solution, G20, Pandemic, Health, Social change, Multimedia, Africa Centres for Disease Control and Prevention, Vaccine hesitancy, Third World Network, CDC, UNAIDS, Education, World Trade Organization, Knowledge, Awareness, Multilateralism, Oxfam, Entertainment Industry Foundation, Ford Motor Company, COVID-19, Research, Safety, Organization, United Nations, Investment, 2020 extraordinary G20 summit on COVID-19, Movement, HIV, Vaccination, Poverty, Pharmaceutical industry, Renewable energy

NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Today, the Ford Foundation announced a special initiative to further global vaccine access and tackle the structural inequities that continue to hinder equal access to COVID-19 vaccines, particularly in the Global South.

Key Points: 
  • NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Today, the Ford Foundation announced a special initiative to further global vaccine access and tackle the structural inequities that continue to hinder equal access to COVID-19 vaccines, particularly in the Global South.
  • Ford's wide range of commitments include signing onto a global effort to distribute vaccines through the People's Vaccine Alliance , a coordinated advocacy campaign to combat vaccine hesitancy and support vaccine access with the Charlize Theron Africa Outreach Project and the Entertainment Industry Foundation , and $16 million in rapid response grants to be deployed across the Global South to strengthen vaccine equity.
  • Multilateral solutions are a vital part of solving global challenges like vaccine access," said Chris Silbermann, chair of the Entertainment Industry Foundation Board.
  • "We commend the Ford Foundation for funding advocacy efforts to increase access to vaccines in the global South so that we can achieve our common goal of vaccine equity.

University of Phoenix Nursing Faculty Participates in Arizona Public Health Association Health Equity Panel

Retrieved on: 
Tuesday, October 5, 2021
Nursing, Education, Health, Infectious Diseases, Continuing, University, Health equity, COVID-19, DNP, RN, Evaluation, Upcoming, Student, Vaccine hesitancy, University, Careers New Zealand, Pacific Islander, Phoenix College, Data, PST, Vaccination, University of Phoenix, Medicine, Pharmaceutical industry

University of Phoenix College of Nursing faculty Sun Jones, DNP, RN, FNP-BC, who serves as the Systematic Plan for Evaluation and Curriculum leader, will join the first in a two-part panel series on Covid-19 and health equity hosted by Arizona Public Health Association (AZPHA) this Friday, October 8, 2021, 9 a.m. 10 a.m. PST.

Key Points: 
  • University of Phoenix College of Nursing faculty Sun Jones, DNP, RN, FNP-BC, who serves as the Systematic Plan for Evaluation and Curriculum leader, will join the first in a two-part panel series on Covid-19 and health equity hosted by Arizona Public Health Association (AZPHA) this Friday, October 8, 2021, 9 a.m. 10 a.m. PST.
  • The panel events, Covid-19 & Health Equity in Arizona, will be held in a virtual panel discussion format, in two parts: Part I: How Are We Reaching Communities on Friday, October 8, and Part II: Where Is The Data Leading Us?
  • Dr. Jones works closely in support of the Phoenix area community to ensure vaccine and treatment access to its citizens.
  • University of Phoenix is continually innovating to help working adults enhance their careers in a rapidly changing world.

Lazard Releases 2021 Global Healthcare Leaders Study

Retrieved on: 
Monday, September 27, 2021
Medical Devices, Infectious Diseases, Hospitals, Finance, Consulting, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Lazard, Biotechnology, CNS, Lists of countries and territories, Clinical trial, LAZ, Tax, LTD, RNA, M&A, Therapy, SPAC, Precision medicine, Central, Vaccine hesitancy, Â, Central nervous system, Industry, Initial public offering, Environment, City, Growth, Leadership, Risk, COVID-19, Technology, Uncertainty, IPO, Automation, Health care, Latin America, Medical device, Movement, NYSE, Study, Travel, Pharmaceutical industry, Retail, Healthcare, Fine chemical, Management

Lazard Ltd (NYSE: LAZ) today released its fourth annual in-depth study of strategic challenges and opportunities in the global healthcare industry, surveying 200 C-level executives and investors across three global sectors: Biopharmaceuticals; Medical Devices and Diagnostics; and Healthcare Services.

Key Points: 
  • Lazard Ltd (NYSE: LAZ) today released its fourth annual in-depth study of strategic challenges and opportunities in the global healthcare industry, surveying 200 C-level executives and investors across three global sectors: Biopharmaceuticals; Medical Devices and Diagnostics; and Healthcare Services.
  • In last years study, there was a high correlation between healthcare industry leaders responses and the subsequent course of events.
  • The Global Healthcare Leaders Study surveyed 171 C-level executives and 29 investors across three sectors: Biopharmaceuticals; Medical Devices and Diagnostics; and Healthcare Services.
  • The Global Healthcare Leaders Study reflects Lazards approach to long-term thought leadership, commitment to the sectors in which it participates, and focus on intellectual differentiation.

PharmaJet selected to deliver Scancell COVID-19 DNA Vaccines

Retrieved on: 
Tuesday, September 14, 2021
Research, General Health, Pharmaceutical, Hardware, Medical Devices, Technology, Infectious Diseases, Clinical Trials, Science, FDA, Other Science, Health, Program, Infection, African, Certification, Severe acute respiratory syndrome coronavirus 2, PQS, University, CEO, U.S. FDA, Vaccine hesitancy, Research, WHO, Use, COVID-19, System, LinkedIn, DNA, Therapy, Vaccine, Injection, Review, RNA, Measles, Cancer, CE marking, Nottingham Trent University, PharmaJet, Scancell, PHARMAJET, SCANCELL

PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner, Scancell , has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2.

Key Points: 
  • PharmaJet , the maker of innovative, needle-free injection technology, today announced that its partner, Scancell , has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2.
  • The vaccines will be exclusively administered using the PharmaJet Tropis and PharmaJet Stratis Needle-free Injection Systems.
  • Preclinical studies have confirmed that PharmaJet delivery of the COVIDITY vaccines induces potent immune responses against both S and N antigens.
  • Our Needle-free Systems have shown improved immune response for multiple DNA and RNA vaccines and are used globally to deliver vaccines for diseases such as influenza, Covid-19 , measles and polio.

Advanced Proteome Therapeutics Provides Update on COVID Program

Retrieved on: 
Tuesday, August 24, 2021
Company, Face, FSE, Protease, Sanofi, COVID, Program, Therapy, Proteome, Severe acute respiratory syndrome coronavirus 2, Cysteine, Pharmacokinetics, APT, APTI, APC, Vaccine hesitancy, COVID-19, Partnership, Vaccine, CEO, Technology, Pharmaceutical industry, Fine chemical

Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Key Points: 
  • Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.
  • In fall of last year, the program was deprioritized in the setting of highly efficacious vaccines entering the market and the promise that the COVID pandemic could be controlled.
  • Dr. Michael Angelastro commented, "I am excited to be working with Advanced Proteome on this project.
  • Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads.

33% of unvaccinated Americans say they will never get vaccinated according to Premise Data survey

Retrieved on: 
Monday, August 23, 2021
Population, COVID, Government, Machine learning, Multimedia, Safety, Vaccine hesitancy, SAN, Vaccine, CEO, Organization, Vaccination, COVID-19, Smartphone, Online shopping, Pharmaceutical industry

Premise's survey was conducted through its app at a speed and scale not traditionally seen in polling.

Key Points: 
  • Premise's survey was conducted through its app at a speed and scale not traditionally seen in polling.
  • The results revealed important distinctions among unvaccinated populations in the U.S. and U.K. and show varying levels of resistance to vaccination.
  • The survey also highlights possible openings which could be used to persuade the unvaccinated to become vaccinated.
  • 33% of unvaccinated Americans and 23% of unvaccinated U.K. citizens said they would never get vaccinated.